Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 17/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24852983 | 1.00 | STING1 (0.57) | STING1PDE3BPDE3A | |
| SCHEMBL24852828 | 1.00 | STING1 (0.57) | STING1PDE3BPDE3A | |
| SCHEMBL24852984 | 0.85 | STING1 (0.47) | STING1PDE3BPDE3A | |
| SCHEMBL22589704 | 0.83 | STING1 (0.53) | STING1PDE3BPDE3A | |
| SCHEMBL13341136 | 0.83 | STING1 (0.77) | STING1PDE3BPDE3A | |
| SCHEMBL13341164 | 0.83 | STING1 (0.77) | STING1PDE3BPDE3A | |
| SCHEMBL29885238 | 0.83 | STING1 (0.77) | STING1PDE3BPDE3A | |
| SCHEMBL23477127 | 0.83 | STING1 (0.77) | STING1PDE3BPDE3A | |
| SCHEMBL9926172 | 0.83 | STING1 (0.77) | STING1PDE3BPDE3A | |
| SCHEMBL21418863 | 0.82 | STING1 (0.49) | STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000890-A1 | Prodrugs of Deoxynucleosides for Treatment of Mitochondrial Diseases Caused by Unbalanced Nucleotide Pools | UCB BIOSCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000890-A1 | Prodrugs of Deoxynucleosides for Treatment of Mitochondrial Diseases Caused by Unbalanced Nucleotide Pools | TK2, NME4, PNP | STING1 1390/4885PDE3B 1696/4885PDE3A 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.